Long DAPT — Competitive Intelligence Brief

Long DAPT (Long DAPT) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet therapy regimen. Area: Cardiovascular.

phase 3 Antiplatelet therapy regimen P2Y12 receptor and cyclooxygenase (COX) Cardiovascular Small molecule

Target snapshot

Long DAPT (Long DAPT) — Federico II University. Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Long DAPT TARGET	Long DAPT	Federico II University	phase 3	Antiplatelet therapy regimen	P2Y12 receptor and cyclooxygenase (COX)
De-escalated Dual Antiplatelet Therapy	De-escalated Dual Antiplatelet Therapy	China National Center for Cardiovascular Diseases	marketed	Antiplatelet therapy regimen
short postimplantation dual antiplatelet therapy	short postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet therapy regimen class)

1. China National Center for Cardiovascular Diseases · 1 drug in this class
2. Federico II University · 1 drug in this class
3. National Institute of Cardiology, Warsaw, Poland · 1 drug in this class